Moxifloxacin Micro Labs (Moxifloxacin)

Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This blockade prevents bacterial cell division and leads to bacterial cell death, providing a bactericidal effect against a broad range of Gram‑positive and Gram‑negative bacteria.

The dosage of moxifloxacin is determined by the prescribing clinician based on the type and severity of the infection, patient age, renal function, and other clinical factors. Only a qualified healthcare professional should set the appropriate regimen.

Safety data for moxifloxacin in pregnancy and lactation are limited, and the pregnancy category is unknown. It should only be used during pregnancy or while breastfeeding when the potential benefits outweigh the possible risks, and after careful assessment by a healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity against atypical respiratory pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a longer half‑life, allowing once‑daily dosing, but shares class‑related safety considerations that require careful patient selection.

Store the product at room temperature, preferably below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Moxifloxacin Micro Labs is administered orally, typically as a tablet swallowed with a full glass of water. It may be taken with or without food, but patients should follow the specific instructions provided by their prescriber.

Serious risks include tendon rupture (especially the Achilles tendon), QT interval prolongation that can lead to arrhythmias, and severe hypersensitivity reactions such as anaphylaxis. Patients should be advised to seek immediate medical attention if they experience sudden tendon pain, palpitations, or signs of an allergic reaction.

Moxifloxacin should be avoided in patients with a known hypersensitivity to fluoroquinolones, a history of tendon disorders related to fluoroquinolone use, or those taking other medications that significantly prolong the QT interval. Caution is also warranted in patients with severe renal impairment or uncontrolled epilepsy.